Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Ashok Gupta | Researchclopedia

Back to researchers

Ashok Gupta

NIMS University

450

Works

38,738

Citations

49

h-index

162

i10-index

Research Topics

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Cytokine Signaling Pathways and Interactions

Affiliations

AstraZeneca (United Kingdom)2018–2020

Advanced Materials and Processes Research Institute2024–2024

Government Medical College2024–2024

Apollo Hospitals2012–2012

Memorial Sloan Kettering Cancer Center2013–2013

Top Works

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian,F. Stephen Hodi,et al.

201212,535 citations

Bladder and Urothelial Cancer Treatments

Cancer Genomics and Diagnostics

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer,Scott S. Tykodi,et al.

20127,944 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok,Harriet M. Kluger,et al.

20134,208 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian,Mario Sznol,et al.

20142,198 citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger,Leora Horn,et al.

20151,189 citations

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles,Peter H. O’Donnell,et al.

2017843 citations

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard,Michael S. Gordon,et al.

2016840 citations

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia,Sarah B. Goldberg,et al.

2016591 citations

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Thomas Powles,Michiel S. van der Heijden,et al.

2020489 citations